Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia (Q80379008)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 January 2007

Language	Label	Description	Also known as
English	Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia	scientific article published on 01 January 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523753%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523753%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

based on heuristic

inferred from title

author name string

Theodore Darkow

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523753%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Henry J Henk

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523753%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Simu K Thomas

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523753%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Weiwei Feng

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523753%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Jean-Francois Baladi

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523753%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

George A Goldberg

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523753%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Alan Hatfield

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523753%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Jorge Cortes

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523753%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523753%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523753%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523753%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523753%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

481-496

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523753%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

https://scigraph.springernature.com/pub.10.2165/00019053-200725060-00004

0 references

Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of ICD-9 coding as a proxy for stage of disease in lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of medication adherence on hospitalization risk and healthcare cost

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Burden of pancreatic cancer and disease progression: economic analysis in the US.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term adherence with cardiovascular drug regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Compliance with treatment regimens in chronic asymptomatic diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interventions for enhancing medication adherence

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A review of the literature on the economics of noncompliance. Room for methodological improvement

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adherence to therapy with oral antineoplastic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of early stage disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of Concurrent Medication Use on Statin Adherence and Refill Persistence

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adherence to Medication

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The assessment of refill compliance using pharmacy records: methods, validity, and applications

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The logged dependent variable, heteroscedasticity, and the retransformation problem.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib mesylate--a new oral targeted therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adherence and persistence with fluticasone propionate/salmeterol combination therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Using drug claims data to assess the relationship of medication adherence with hospitalization and costs

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Electronic monitoring and counseling to improve medication adherence

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of number of medications on cardiovascular therapy adherence

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib mesylate--gold standards and silver linings

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib mesylate, the first molecularly targeted gene suppressor

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of medication-refill adherence in an indigent rural population

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of adherence with antihypertensive and lipid-lowering therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/17523753

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80379008&oldid=2136156137"